Seaport Therapeutics' GlyphAllo Clears Driving Impairment Test, Advancing MDD Treatment
Event summary
- Seaport Therapeutics' Phase 1 trial showed GlyphAllo at 375 mg did not impair next-morning driving performance in healthy volunteers.
- The trial met both primary and key secondary endpoints, with no serious adverse events reported.
- Seaport plans to submit results to the FDA and expects topline data from the Phase 2b BUOY-1 trial in H1 2027.
- GlyphAllo is a novel oral prodrug of allopregnanolone, targeting major depressive disorder (MDD).
The big picture
Seaport Therapeutics' positive Phase 1 data for GlyphAllo reinforces the potential of its Glyph platform to overcome bioavailability limitations of neuropsychiatric drugs. The results come at a time when the MDD market is seeing increased innovation, with a focus on rapid-acting and well-tolerated therapies. The next critical step will be the Phase 2b trial, which could position GlyphAllo as a first-in-class treatment if successful.
What we're watching
- Regulatory Pathway
- Whether the FDA will view the driving simulation data as sufficient to support GlyphAllo's development for MDD.
- Clinical Validation
- The pace at which Seaport can enroll and complete the Phase 2b BUOY-1 trial, given the competitive landscape in MDD treatments.
- Market Differentiation
- How GlyphAllo's lack of next-morning driving impairment will position it against existing and emerging antidepressants.
Related topics